PPD ACT is a research study developed by Postpartum Depression: Action Towards Causes and Treatment (PACT) Consortium, an international group of academic clinicians and scientists committed to understanding the interaction of genes and environment to predict which women are at risk of postpartum depression (PPD).

Download free iOSand free android mobile app to participate.

Sage is currently conducting two multi-center, randomized, double-blind, parallel-group, placebo-controlled Phase 3 studies evaluating the efficacy, safety and pharmacokinetics of brexanolone injection in the treatment of adult female subjects with moderate to severe postpartum depression. One of the Phase 3 studies is evaluating dose ranges of brexanolone in severe PPD patients and the other Phase 3 study is evaluating brexanolone treatment in moderate PPD patients.